According to a report published in the most recent issue of the Journal of the American Medical Association, scientists were able to determine that 6 percent of pregnancies after contracting the Zika virus infection resulted in one or more birth defects linked to Zika using data from the U.S. Zika Pregnancy Registry. Read More »
Legislators in Missouri will move in the next session to bring the state into line with most of the rest of the country by heightening the standard on expert witness testimony in civil trials. Read More »
Express Scripts' enhancements have been applied to its SafeGuardRx programs, which focus on the treatment of hepatitis C and cancer. Read More »
According a new research study conducted by Visante, pharmacy benefit managers are saving consumers and payers $941 on average per person a year. Read More »
In the dance between drug and insurance companies over the cost of medicines and which ones should be prescribed, step therapy or “fail first” policies are increasingly popular. Read More »
CymaBay Therapeutics will present results of its Phase 2 proof-of-concept MBX-8025 clinical trial at the Annual Meeting of the American Association for the Study of Liver Diseases Nov. 11-15 in Boston. Read More »
Coupons offered by drug companies play a significant role in keeping prescription costs high, according to the co-author of a report that lays out solutions to fix problems with the system. Read More »
Co-pay coupons and discounts offered to consumers ultimately will lead to higher costs across society as they increasingly drive up premiums, according to one leading expert on prescription drugs. Read More »
At first, price-slashing discount coupons for expensive drugs may appeal to consumers on an everyday basis, but a look behind the scenes suggests that using brand-name medications may possibly yield little, if any, net savings. Read More »
Sen. Kelly Ayotte (R-NH) has been honored for her work in driving a bill through Congress aimed at battling the opioid, heroin and fentanyl abuse epidemic. Read More »
Medicaid could see $51.1 billion over the next decade if a “full range of pharmacy benefit management tools” is employed, according to a new report completed by The Menges Group and released by the Pharmaceutical Care Management Association (PCMA). Read More »
Hepatitis C medication costs in 2015 proved lower for the U.S. than Europe and Japan, particularly prices negotiated by pharmacy benefit managers in Medicare Part D, the Pharmaceutical Care Management Association recently reported. Read More »
As debate rages over drug prices, one of the country’s largest pharmacy benefit managers is touting biosimilars as a way of achieving significant savings over the next five years. Read More »
The experience of Mylan, the pharmaceutical company under fire for hiking the price of a life-saving allergy medicine, reinforces the importance of competition in the marketplace, one of the country’s largest pharmacy benefit managers said. Read More »
Recent survey results conducted by North Star Opinion Research and released by an industry association confirm that 60 percent of U.S. employers believe new federal oversight would lead to higher prescription-drug costs. Read More »
A single industry-sponsored meal is enough to sway a doctor to prescribe a brand-name drug rather than a cheaper but just as effective generic, a study by the University of San Francisco has found. Read More »
If drug manufacturers ever wonder whether they have a collective image problem, the answer is yes, according to a recent Gallup poll. Read More »
A ballot initiative supporters claim will lower drug prices in California is vague and poorly conceived, said a group with a long history of advocating for better cures and treatment for HIV and hepatitis C. Read More »
A majority of health care plans and programs with a drug exclusion policy have been successful, reducing costs and not negatively impacting patient care, concludes a new study published in The American Journal of Managed Care. Read More »
Managing and monitoring the increasingly high cost of speciality drugs will be a key challenge to control insurance prices over the next two years, say employers and third party payers. Read More »
Alerts Sign-up
